An innovative pharmaceutical company based in Japan and Glenmark Life Sciences have inked a Master Supply Agreement (MSA). Glenmark Life Sciences will produce API for the Japanese company in the therapeutic field of urinary anti-spasmodics within the terms of the Master Supply Agreement.
Product portfolios from other Japanese firm affiliates may be included in the future as part of this collaboration. The API for the completed formulation will be delivered to the US, Europe, and Japan, three significant regulated markets. This project is predicted to have a commercial value of approximately $5 million.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
